



December 14, 2018

Dear Fellow Stockholders,

2018 was an exciting fiscal year for Brooks Automation and the customers we serve. Our momentum continued with revenue growth of 20% and adjusted EPS growth of 44%. This follows on the heels of 22% growth in fiscal 2017. In 2018 we added significant new customer relationships and expanded our portfolio of high growth offerings. Even though we significantly outgrew the market in both of our segments, automation solutions for the semiconductor capital equipment sector and comprehensive sample-based services for life sciences customers, we have not become complacent. In the fourth quarter of fiscal 2018, we announced two significant business transactions that have moved us further on our path of strategic transformation as we move into 2019.

As I write this letter, we are in the first 30 days of operations with our newly acquired GENEWIZ business, the latest addition to our Life Sciences offerings. Gene sequencing and synthesis services add a significant dimension of science to our offerings, another \$120 million of revenue base to our Life Sciences business, and a more comprehensive and valuable solution set to our customers. Our team is also busy at work in completing the steps that are required to divest our semiconductor cryogenics business, a transaction we announced in August. The \$675 million sales price will provide significant capital for investments to serve growth areas. We expect the transaction to close in our second fiscal quarter of 2019. While this sale will reduce our revenue and earnings base, we have described to investors our targets to replace the revenue within 2019, and the earnings within 2020, providing a faster ramp of growth for years to come.

Our revenue and earnings growth continued in 2018

Semiconductor Solutions Group

Fiscal 2018 started with continued momentum from a strong semiconductor capital equipment market but ended with lower spending amid increased uncertainty. Through this swing, we have continued to outpace the industry, with total semiconductor revenue of \$631 million, an increase of 16% over fiscal 2017. Our three high growth drivers continue to be: (1) vacuum automation, which is integral to deposition and etching process equipment; (2) contamination control solutions for yield improvement for our leading edge fab customers; and (3) automation systems for advanced packaging technologies for integrated circuits. We meaningfully grew our market share and revenue in vacuum automation and advanced packaging, and while revenue from contamination control was lower in 2018 compared to an historically high 2017, we achieved significant qualifications in additional customer fabs, assuring us of the continued expansion and of clear position as the market leader in this nascent, yet important segment. We also added to our contamination controls solutions business in 2018 with the acquisition of Tec-Sem, bringing highly capable reticle management solutions into our portfolio.

Life Sciences

Last year, we noted that the life sciences market was in the middle of one of the most exciting periods of scientific and medical breakthroughs of the past century, with approval of the first clinical cell therapy treatments, and the cost of mapping the individual genome reduced dramatically, fueling the collection of an enormous number of biological samples that will be valuable scientific assets for years to come. A year later, we are more convinced that these factors portend a unique and compelling growth opportunity as we expand our position as the leading provider of comprehensive solutions for management of biological and compound samples. In 2018, our Life Sciences segment revenue grew 32% to \$197 million, propelled by 14% organic growth. Meaningfully, we saw a breakthrough in the adoption, by one of the leaders in cell therapy, of our cryogenic sample management offering,

the BioStore™ III Cryo, which operates at -196°. We also completed two acquisitions during the year – BioSpeciMan, and 4titude – and, of course, we just added GENEWIZ in November 2018.

Solid Science, Superior Service

With the acquisition of GENEWIZ we are in the midst of a transformative expansion of our Life Sciences platform. GENEWIZ comes with an annual revenue run rate above \$120 million and historical top line growth of more than 20% per year. GENEWIZ's offerings include the writing and reading of genes, providing a critical step of consultative science via a high quality and expedient service delivery model. While our Life Sciences business has grown to serve over 1,200 customers in 2018, GENEWIZ supports more than 4,000 customers. As we embark on the integration of our two companies, we are excited to bring additional benefits to those customers who are already common customers, and we are equally bullish about the value we can add to those who are not yet served by both companies.

Looking Forward

We enter 2019 on a new trajectory that is the result of our product and technology investments, and the meaningful transformation we have made through acquisitions and divestitures that have reshaped our portfolio for more high growth. Our Life Sciences business is positioned to continue its growth trend, now with the expanded size and scope of the GENEWIZ business. Our Semiconductor Solutions business will capitalize on high growth segments and we remain confident in our ability to perform ahead of the semiconductor capital equipment market. When we exit 2019, we expect Life Sciences revenue to make up 40% of our total revenue – a significant milestone in our transformation. We at Brooks are extremely proud of our fiscal 2018 results and excited about what lies ahead in 2019. On behalf of our Board of Directors and the entire global Brooks team, we thank each of our stockholders for their continued support and confidence.

Sincerely,

A handwritten signature in black ink, appearing to read "Steve Schwartz", written in a cursive style.

Steve Schwartz
Chief Executive Officer